Disclosures for "Case Report of an Incidental Suprasellar Anaplastic Hemangiopericytoma"
-
Dr. Persico has nothing to disclose.
-
Dr. Shu has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novocure. Dr. Shu has stock in Gilead. Dr. Shu has stock in Akebia Therapeutic. The institution of Dr. Shu has received research support from Novocure.
-
Dr. Zhong has nothing to disclose.